Russian drugs are increasing their share in oncology and hepatitis market segments

In 2017, the share of Russian medicines for the treatment of oncological diseases reached almost 50% in this market segment. Over the past five years (since 2012), this figure increased by 3.6 times (from 13.2% to 46.9%). This is confirmed by the data released in the report of the Russian Ministry of Industry and Trade for 2017.

Russian drugs have a larger share only in the segment of vital and essential drugs (VED List). According to the Ministry of Industry and Trade, last year, it exceeded 84%.

In the five years, the largest increase was achieved in the share of Russian medicines for the treatment of hepatitis. In 2017, it reached 31.6%. This is six times more than in 2012, when the corresponding figure was 5.3%.

The share of Russian drugs for the treatment of HIV infection has doubled (27.4% in 2017 vs. 13.2% in 2012).

The increase is also reported in the category of Seven Nosologies. This includes the drugs for the treatment of hemophilia; cystic fibrosis; pituitary dwarfism; Gaucher disease; malignant neoplasms of lymphoid, haematopoietic and related tissue; multiple sclerosis, as well as conditions after organ transplantation.

The federal program of Seven Nosologies is in place since 2008 in order to provide expensive medicines to Russian patients affected by these severe and rare diseases. Over the past five years, the share of Russian medicines in this segment increased from 10.2% to 39.2%.